Keytruda Just Got Its First Publicly Announced Biosimilar Challenger, and the Prize Is $31.7 Billion
Zydus and Formycon say their Keytruda copycat is the first publicly announced to get FDA review. Here's what it means for cancer drug costs.
Cancer Drugs
Local weather
Finding your area…National Weather Service
Trending
- College Football Week 6 Guide: Georgia-Alabama, Red River and Every Big Game to Watch
- Keytruda Just Got Its First Publicly Announced Biosimilar Challenger, and the Prize Is $31.7 Billion
- FDA Clears a Lung-Clot Removal System That Gives Patients Their Own Blood Back
- Stellantis CEO Says the US EV Boom Was a ‘Bubble,’ and Americans Will Come Around Slowly
- Anthropic Warns Your $55 TV Box Could Become an AI’s Next Home